HC Wainwright & Co. Upgrades Sana Biotechnology to Buy, Announces $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has upgraded Sana Biotechnology (NASDAQ:SANA) from Neutral to Buy and set a price target of $12.
January 16, 2024 | 4:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sana Biotechnology was upgraded by HC Wainwright & Co. from Neutral to Buy with a price target of $12, indicating a positive outlook on the stock.
Upgrades by analysts, especially with a significant price target increase, tend to lead to short-term positive sentiment and potential stock price increases as investors react to the new information.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100